christof retweeted
And the #UromigosLive World Cup FINAL champions are… 🏆🇧🇪 Team Belgium! Congratulations @cvulsteke @BlancJeremy with help from 🇫🇷 for the final round!
🥈 Kudos to Team Netherlands 🇳🇱 for a fantastic 2nd place!
What a competition! Huge thanks to @tompowles1 for keeping us all on our toes with his fun, evolving rules, spontaneous twists, and improvisation with help from audience along the way! ⚽🌍
@OncoAlert @brian_rini @Uromigos @uromigosjapan @LosUromigos @adidhanawat @montypal @PGrivasMDPhD @neerajaiims @NehaVapiwala @giannatempopatr @CMercinelli @kalasri3 @UroDocAsh
christof retweeted
Team Belgium is proud to welcome his honorary member at #UromigosWorldCup. Lets the competition begin ! @Uromigos @cvulsteke @tompowles1
christof retweeted
🇪🇺 Europe is here at the #UromigosWorldCup! 🏆⚽
Fierce competitors but united by our passion for science, collaboration, fun!
Different countries, one European spirit! 💪🇪🇺
#Uromigos @ViktorGruenwald @LAUrology_NL @AlbigesL @CMercinelli @Anto_cigliola @cvulsteke @BlancJeremy
🇧🇪 The Red Devils are ready to raise some hell at the Uromigos World Cup! ⚽🏆
From the historic streets of Ghent, Team Belgium is tackling a big question in metastatic bladder cancer: When can patients safely stop immunotherapy?
On the pitch and in research, teamwork makes the difference!
#UromigosLive
christof retweeted
The European Commission approved perioperative pembrolizumab plus enfortumab vedotin for patients with cisplatin-ineligible resectable MIBC. @cvulsteke #blcsm #oncology
onclive.com/view/perioperati…
christof retweeted
The 2nd UroOncoJourney in Rome 🇮🇹, was a great success! More than 140 participants, great speakers and a recognized place to discuss 1y of news in GU cancers! Special thank to @cvulsteke and to @cosimodenunzio @Albert0Briganti @BovePierluigi @GiuliaMarvaso84 @PasRescigno @alongi_filippo @SciarraUrology @AndreaTubaro @LuigiFormisano_ @ciccarese_c @GFornarini @RoccoPapaliaUro @MariaChiaraMCS @Sebastiano_Buti @giannatempopatr and many others. See you next year! @OncoAlert @oncodaily @OncoDailyGU @urofocus
christof retweeted
🆕 phase III data in cisplatin-ineligible #MIBC:
Perioperative enfortumab vedotin + pembrolizumab improved outcomes vs surgery alone.
📊 pCR: 57.1% vs 8.6%
📈 Improved EFS & OS
⚠️ More grade ≥3 AEs
🩺 Christof Vulsteke, MD, PhD (@cvulsteke) | @NEJM
🔗 ascopost.com/news/march-2026…
christof retweeted
🧬 Phase III KEYNOTE-905: In cisplatin-ineligible #MIBC, perioperative enfortumab vedotin + pembrolizumab improved outcomes vs surgery alone.
▫️ 2-yr EFS: 74.7% vs 39.4%
▫️ 2-yr OS: 79.7% vs 63.1%
👨⚕️ Christof Vulsteke, MD, PhD (@cvulsteke) | @NEJM
🔗 ascopost.com/news/march-2026…
A paradigm shift in bladder Cancer Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer | New England Journal of Medicine nejm.org/doi/full/10.1056/NE… @shilpaonc @y_loriot
christof retweeted
Results from the phase 3 Keynote-905/EV-303 now available.
Congrats to the investigators.
@cvulsteke
#OncoAlert
#CTUIntegratedCancerCenterGhent
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG
Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer | New England Journal of Medicine
nejm.org/doi/full/10.1056/NE…
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG
Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T
christof retweeted
EV/Pembro has another positive trial (EFS & OS) in MIBC. This time vs chemo/surgery rather than just surgery (KN905 (pCR 57%)). Will these results be better than NIAGARA (chemo/durva OS-0.75). In M1 disease EVP>chemo/IO, but let’s see in MIBC. pfizer.com/news/press-releas…
christof retweeted
🎯 the Eurasia team are now 6-0 ahead for the Uromigos cup 🏆 @MichvdHeijden is part of the team November 7th and 8th in Nashville. Here he is in beautiful Amsterdam among the canals 🇳🇱 🇳🇱 🇳🇱 🇳🇱 🇳🇱. Hearts ♥️ points. @OncoAlert
christof retweeted
🚨 In this episode Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC.
🎙️ GU Oncology Now: buff.ly/IO0QYVX
🍎 Apple Podcasts: buff.ly/IO0QYVX
🎧Spotify: buff.ly/SWAS0z7
christof retweeted
#ESMO25 had 4 GU trials in the Presidential plenary sessions! @myESMO
On behalf our GU team, was proud to represent @CleClinicMD for 3/4! #IMvigor011, KN-905 and PSMAddition! Truly grateful to patients & families, my co- investigators & clinical research team for helping us make meaningful contributions to these practice changing trials!
@AmandaNizamMD @ChrisWeeMD @MosheOrnsteinMD @TimGilliganMD
christof retweeted
2/5 KN905 #ESMO25: Perioperative EVP in MIBC shows ⬆️ EFS,OS & pCR vs cystectomy alone in cisplatin ineligible MIBC. Gem/cis durvalumab showed pCR=37% & OS HR of 0.75. Will EVP be much better? Will it only apply to the cisplatin ineligible population? Will we see pembro only arm?
christof retweeted
Witnessed the incredible energy of the @myESMO Scientific Chairs this year. @DrChoueiri & @MyriamChalabi have put together a dazzling program. Check out the #ESMO25 Presidential Session titles 👇
christof retweeted
Congrats @DrChoueiri @MyriamChalabi on lining up such a fantastic @myESMO
Amazing to see 4 GU abstracts in the Presidential session!
Kudos to the GU scientific committee chair @montypal
@neerajaiims @PGrivasMDPhD @tompowles1 @Uromigos







































